Russell Gollard, MD
Hematology & Oncology · Henderson, NVNPI 1699772210
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Sobi, Inc at 24.9% of the total. 2025 is the largest year on record at $44,563, 4.6 times the $9,773 reported in 2019. Among hematology & oncology clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 600 payments — averaging $175.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$26K
- AstraZeneca$11K
- EMD Serono, Inc.$8K
- Mirati Therapeutics, Inc.$6K
- Bristol Myers Squibb$5K
- Syndax Pharmaceuticals, Inc.$5K
- plus $44K from 54 others
Across 15 payments — averaging $13,441 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$91K
- Morphosys AG$59K
- AstraZeneca$28K
- Janssen Research & Development, LLC$12K
- Sanofi US Services Inc.$11K
- Astrazeneca UK Limited$820
What the payments were for
- Consulting fees$45,18943%
- Speaking & faculty fees$41,76640%
- Travel & lodging$2,0062%
- Food & beverage$13,84513%
- Education$2,5512%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$105,357 in reported general payments places this provider in the 90th percentile of 82 hematology & oncology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 69 | $1,289,313 |
| PomalystPomalidomide | 29 | $723,127 |
| CalquenceAcalabrutinib Maleate | 46 | $722,914 |
| ImbruvicaIbrutinib | 41 | $719,056 |
| LynparzaOlaparib | 23 | $430,679 |
| KeytrudaPembrolizumab | 34 | $411,137 |
| Lenalidomide | 31 | $345,215 |
| NerlynxNeratinib Maleate | 12 | $308,413 |
| BosulifBosutinib | 13 | $302,769 |
| GilotrifAfatinib Dimaleate | 13 | $286,380 |
| ErleadaApalutamide | 14 | $242,194 |
| EliquisApixaban | 175 | $135,677 |
| Abiraterone Acetate | 78 | $62,604 |
| ImfinziDurvalumab | 12 | $32,889 |
| XareltoRivaroxaban | 36 | $21,038 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $5,112 | $1,289,31369 claims |
| AstraZenecaCalquence, Lynparza, Imfinzi | $10,690 | $1,186,48281 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $579 | $723,12729 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $360 | $719,05641 claims |
| PfizerBosulif, Eliquis | $639 | $438,446188 claims |
| MerckKeytruda | $246 | $411,13734 claims |
| Boehringer IngelheimGilotrif | $46 | $286,38013 claims |
| Johnson & JohnsonErleada, Xarelto | $605 | $263,23250 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $176 | $62,60478 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 82 hematology & oncology providers in Nevada.
Other hematology & oncology in Henderson
- Anthony NguyenHenderson$210K
- Rupesh ParikhHenderson$67K
- Ramalingam RatnasabapathyHenderson$25K
- Stephani ChristensenHenderson$10K
- Resty TibayanHenderson$10K
- Nutan ParikhHenderson$10K
- Muhammad GhaniHenderson$9K
- Khoi DaoHenderson$8K
- Gilbert NyamuswaHenderson$4K
- Nicholas VogelzangLas Vegas$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.